Findings of Research Misconduct, 8148-8149 [2013-02487]

Download as PDF 8148 Federal Register / Vol. 78, No. 24 / Tuesday, February 5, 2013 / Notices A copy of the charter for the 2015 DGAC can be obtained from the designated contacts. A copy of the charter also will be made available on the FACA database after the document is filed with the appropriate Congressional committees and the Library of Congress. The FACA database is a shared management system that is maintained by the GSA Committee Management Secretariat. The Web site for the FACA database is https://fido.gov/ facadatabase/. Dated: January 30, 2013. Howard K. Koh, Assistant Secretary for Health. [FR Doc. 2013–02502 Filed 2–4–13; 8:45 am] BILLING CODE 4150–32–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct Office of the Secretary, HHS. Notice. AGENCY: ACTION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Bryan William Doreian, Ph.D., Case Western Reserve University: Based on the admission of the Respondent, ORI found that Dr. Bryan William Doreian, former postdoctoral fellow, Department of Dermatology, Case Western Reserve University (CWRU), engaged in research misconduct in research supported by National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), grant T32 HL07887 and National Institute of Neurological Disorders and Stroke (NINDS), NIH, grant R01 NS052123. ORI found that the Respondent engaged in research misconduct by falsifying data that were included in: • Doreian, B.W. ‘‘Molecular Regulation of the Exocytic Mode in Adrenal Chromaffin Cells.’’ Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy, August 2009; hereafter referred to as the ‘‘Dissertation.’’ • Doreian, B.W., Fulop, T.G., Meklemburg, R.L., Smith, C.B. ‘‘Cortical F-actin, the exocytic mode, and neuropeptide release in mouse chromaffin cells is regulated by myristoylated alanine-rich C-kinase substrate and myosin II.’’ Mol Biol Cell. 20(13):3142–54, 2009 Jul; hereafter referred to as the ‘‘Mol Biol Cell paper.’’ • Doreian, B.W., Rosenjack, J., Galle, P.S., Hansen, M.B., Cathcart, M.K., tkelley on DSK3SPTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 17:18 Feb 04, 2013 Jkt 229001 Silverstein, R.L., McCormick, T.S., Cooper, K.D., Lu, K.Q. ‘‘Hyperinflammation and tissue destruction mediated by PPAR-g activation of macrophages in IL–6 deficiency.’’ Manuscript prepared for submission to Nature Medicine; hereafter referred to as the ‘‘Nature Medicine manuscript.’’ As a result of the Respondent’s admission, the Respondent will request that the following paper be retracted: Mol Biol Cell. 20(13):3142–54, 2009 Jul. ORI finds that Respondent falsified numerical values in the Mol Biol Cell paper, the submitted Nature Medicine manuscript, and the Dissertation by altering the number of samples or the experimental results to improve the statistical results. Specifically, ORI finds that Respondent: 1. Falsified the quantification of immunofluorescence for the ratio of phosphorylated to unphosphorylated MARCKS protein in response to different stimuli in Figure 2 of the Mol Biol Cell paper and in Figure 12 of the Dissertation by falsifying the sample number as n=15. 2. Falsified the quantification of immunofluorescence for filamentous actin in response to different stimuli in Figure 3 of the Mol Biol Cell paper and in Figure 13 of the Dissertation by falsifying the sample number as n=15. 3. Falsified the quantification for the effect of blebbistatin on catecholamine release as determined by patch clamp analysis in Figure 22 of the Dissertation by stating that 14 cells had been assayed when only 8 cells had been assayed. 4. Falsified the Pearson’s crosscorrelation analysis in Figure 7 of the Mol Biol Cell paper and in Figure 25 of the Dissertation, used to calculate the degree of spatial correlation between pan-chromogranin A/B (CgA/B) and the endosomal membrane, by stating that 20 or more cells had been tested for each condition when only 9–18 cells had been tested for each condition. 5. Falsified RT–PCR values for iNOS and TNF-alpha expression recorded on spreadsheets and presented in Figures 5e and 5f of the Nature Medicine manuscript showing the effect of hyperinflammatory macrophage generation on tissue destruction, by falsifying the numeric values to fit the hypothesis of the manuscript. 6. Falsified ELISA graphs for the concentration of TNF-a in the aAB IL– 6 mice and their controls in Figure 6j of the Nature Medicine manuscript showing the effect of rosiglitazone treatment in the mice, by multiplying the experimental values by 100 to match the magnitude of the values presented in Figures 21, 6h, and 6i of the Nature Medicine manuscript. PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 7. Falsified the RT–PCR results presented in the Nature Medicine manuscript for quantification of iNOS and TNF-a RNA expression by claiming that the results represent the rmean of three identical experiments when the three experiments were normalized differently to yield the desired result. Specifically, false results were presented for peritoneal macrophages treated in vivo with rosiglitazone and/ or inhibitors of PPARg signaling Figures 1g, 1h, and 1i, and for iNOS RNA expresssion in IL6-/- macrophages treated in vitro with either SOCS3 antisense oligonucleotides in Figure 2g or the STAT3 decoy in Figure 2j. Dr. Doreian has entered into a Voluntary Settlement Agreement and has voluntarily agreed for a period of three (3) years, beginning on January 15, 2013: (1) To have his research supervised; Respondent agreed that prior to the submission of an application for U.S. Public Health Service (PHS) support for a research project on which his participation is proposed and prior to his participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of his duties is submitted to ORI for approval; the supervision plan must be designed to ensure the scientific integrity of his research contribution; he agreed that he shall not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan; (2) That any institution employing him shall submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; (3) To exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and (4) To request that the following paper be retracted: Mol Biol Cell. 20(13):3142– 54, 2009 Jul. FOR FURTHER INFORMATION CONTACT: Director, Office of Research Integrity, E:\FR\FM\05FEN1.SGM 05FEN1 8149 Federal Register / Vol. 78, No. 24 / Tuesday, February 5, 2013 / Notices 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8200. David E. Wright, Director, Office of Research Integrity. [FR Doc. 2013–02487 Filed 2–4–13; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Extension of a Currently Approved Information Collection; Comment Request Proposed Projects Title: Cross-Site Evaluation of Children’s Bureau’s Child Welfare Technical Assistance Implementation Centers and National Child Welfare Resource Centers. OMB No.: 0970–0377. Background and Brief Description: The Cross-Site Evaluation of the Child Welfare Implementation Centers (ICs) and National Resource Centers (NRCs) is sponsored by the Children’s Bureau, Administration for Children and Families, of the U.S. Department of Health and Human Services and involves the conduct of a multi-year cross-site evaluation that examines the service provision of the ICs’ and NRCs’ and the relation of their training and technical assistance activities to organizational and systems change in State and Tribal child welfare systems. Additionally, the evaluation examines the degree to which networking, collaboration, information sharing, adherence to common principles, and common messaging occurs across members of the Children’s Bureau Training and Technical Assistance (T/ TA) Network, which is designed to improve child welfare systems and to support States and Tribes in achieving sustainable, systemic change that results in greater safety, permanency, and wellbeing for children, youth, and families. The Children’s Bureau desires to assess the quality and effectiveness of the technical assistance it supports, and several of these programs and projects are required to be evaluated, including those funded under Section 105 of The Child Abuse Prevention and Treatment Act, as amended [42 U.S.C. 5106]. The Children’s Bureau T/TA Network is currently comprised of providers funded entirely or partially by the Children’s Bureau through grants, contracts, and interagency agreements. The cross-site evaluation uses a mixed-method, longitudinal approach. Data collection methods that already have been employed are a longitudinal telephone survey of State and Tribal child welfare directors (or their designees), a web-based survey of State and Tribal T/TA recipients, and aggregation of outputs from a web-based technical assistance tracking system (OneNet) that will continue to be used by the ICs and NRCs. A web-based survey also has been administered to members of the T/TA Network to assess their communication, coordination, and how they function as part of the Network. Data collected through these instruments are being used by the Children’s Bureau to evaluate the technical assistance delivered to State, local, Tribal, and other publicly administered or publicly supported child welfare agencies and family and juvenile courts. Extension of the followup data collection instruments beyond the June 30, 2013 expiration date is necessary so that the Children’s Bureau can assess the extent to which its T/TA providers achieve their key objectives and determine the outcomes of the T/ TA from the perspective of States and Tribes, incorporating service utilization data from OneNet into these analyses. Respondents: Respondents to two of the survey instruments will be State and Tribal governments. Respondents to the third survey will be private institutions, including universities, not-for-profit organizations, and private companies. Private institutions, including universities and not-for-profit organizations will be respondents to the forms in the OneNet tracking system. ANNUAL BURDEN ESTIMATES Number of respondents Instrument Number of responses per respondent Average burden hours per response 74 160 15 17 13 13 12 5 5 5 5 1 3 1 11.8 12.31 6.2 160 1.7 4.6 600 36 1.0 0.25 0.25 0.25 0.40 0.28 0.30 0.40 0.28 0.30 0.17 Estimated Total Annual Burden Hours: .......................................... tkelley on DSK3SPTVN1PROD with NOTICES Agency Results Survey ......................................................................... T/TA Activity Survey .............................................................................. Web-Based Network Survey ................................................................. OneNet Form: General T/TA Event ....................................................... OneNet Form: T/TA Request ................................................................ OneNet Form: T/TA Assessment and Work Plan ................................. OneNet Form: T/TA Activity .................................................................. OneNet Form: Implementation Project Application ............................... OneNet Form: Implementation Project Assessment and Work Plan .... OneNet Form: Implementation Project T/TA Activity ............................ OneNet Form: Implementation Project Monthly Report ........................ ........................ ............................ .......................... Overall, the estimated burden hours have decreased by 284 hours from the original submission (the estimated total annual burden hours were 2135.12). This difference is explained in part due to plans for fewer Network member organizations to complete subsequent surveys. Additional data fields have been added to four of the OneNet forms at the request of respondents, and a few questions on survey instruments have VerDate Mar<15>2010 17:18 Feb 04, 2013 Jkt 229001 been removed or revised. These minor changes did not increase the total annual burden hours. Additional Information: Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L’Enfant Promenade SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 Total annual burden hours 74.00 120.00 3.75 50.00 64.00 22.568 576.00 3.4 6.44 900 30.60 1850.76 should be identified by the title of the information collection. Email address: infocollection@acf.hhs.gov. OMB Comment: OMB is required to make a decision concerning the collection information between 30 and 60 days after publication of this document in the Federal Register. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written E:\FR\FM\05FEN1.SGM 05FEN1

Agencies

[Federal Register Volume 78, Number 24 (Tuesday, February 5, 2013)]
[Notices]
[Pages 8148-8149]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-02487]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Bryan William Doreian, Ph.D., Case Western Reserve University: 
Based on the admission of the Respondent, ORI found that Dr. Bryan 
William Doreian, former postdoctoral fellow, Department of Dermatology, 
Case Western Reserve University (CWRU), engaged in research misconduct 
in research supported by National Heart, Lung, and Blood Institute 
(NHLBI), National Institutes of Health (NIH), grant T32 HL07887 and 
National Institute of Neurological Disorders and Stroke (NINDS), NIH, 
grant R01 NS052123.
    ORI found that the Respondent engaged in research misconduct by 
falsifying data that were included in:
     Doreian, B.W. ``Molecular Regulation of the Exocytic Mode 
in Adrenal Chromaffin Cells.'' Submitted in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy, August 2009; 
hereafter referred to as the ``Dissertation.''
     Doreian, B.W., Fulop, T.G., Meklemburg, R.L., Smith, C.B. 
``Cortical F-actin, the exocytic mode, and neuropeptide release in 
mouse chromaffin cells is regulated by myristoylated alanine-rich C-
kinase substrate and myosin II.'' Mol Biol Cell. 20(13):3142-54, 2009 
Jul; hereafter referred to as the ``Mol Biol Cell paper.''
     Doreian, B.W., Rosenjack, J., Galle, P.S., Hansen, M.B., 
Cathcart, M.K., Silverstein, R.L., McCormick, T.S., Cooper, K.D., Lu, 
K.Q. ``Hyper-inflammation and tissue destruction mediated by PPAR-
[gamma] activation of macrophages in IL-6 deficiency.'' Manuscript 
prepared for submission to Nature Medicine; hereafter referred to as 
the ``Nature Medicine manuscript.''
    As a result of the Respondent's admission, the Respondent will 
request that the following paper be retracted: Mol Biol Cell. 
20(13):3142-54, 2009 Jul.
    ORI finds that Respondent falsified numerical values in the Mol 
Biol Cell paper, the submitted Nature Medicine manuscript, and the 
Dissertation by altering the number of samples or the experimental 
results to improve the statistical results. Specifically, ORI finds 
that Respondent:
    1. Falsified the quantification of immunofluorescence for the ratio 
of phosphorylated to unphosphorylated MARCKS protein in response to 
different stimuli in Figure 2 of the Mol Biol Cell paper and in Figure 
12 of the Dissertation by falsifying the sample number as n=15.
    2. Falsified the quantification of immunofluorescence for 
filamentous actin in response to different stimuli in Figure 3 of the 
Mol Biol Cell paper and in Figure 13 of the Dissertation by falsifying 
the sample number as n=15.
    3. Falsified the quantification for the effect of blebbistatin on 
catecholamine release as determined by patch clamp analysis in Figure 
22 of the Dissertation by stating that 14 cells had been assayed when 
only 8 cells had been assayed.
    4. Falsified the Pearson's cross-correlation analysis in Figure 7 
of the Mol Biol Cell paper and in Figure 25 of the Dissertation, used 
to calculate the degree of spatial correlation between pan-chromogranin 
A/B (CgA/B) and the endosomal membrane, by stating that 20 or more 
cells had been tested for each condition when only 9-18 cells had been 
tested for each condition.
    5. Falsified RT-PCR values for iNOS and TNF-alpha expression 
recorded on spreadsheets and presented in Figures 5e and 5f of the 
Nature Medicine manuscript showing the effect of hyper-inflammatory 
macrophage generation on tissue destruction, by falsifying the numeric 
values to fit the hypothesis of the manuscript.
    6. Falsified ELISA graphs for the concentration of TNF-[alpha] in 
the aAB IL-6 mice and their controls in Figure 6j of the Nature 
Medicine manuscript showing the effect of rosiglitazone treatment in 
the mice, by multiplying the experimental values by 100 to match the 
magnitude of the values presented in Figures 21, 6h, and 6i of the 
Nature Medicine manuscript.
    7. Falsified the RT-PCR results presented in the Nature Medicine 
manuscript for quantification of iNOS and TNF-[alpha] RNA expression by 
claiming that the results represent the rmean of three identical 
experiments when the three experiments were normalized differently to 
yield the desired result. Specifically, false results were presented 
for peritoneal macrophages treated in vivo with rosiglitazone and/or 
inhibitors of PPAR[gamma] signaling Figures 1g, 1h, and 1i, and for 
iNOS RNA expresssion in IL6-/- macrophages treated in vitro 
with either SOCS3 antisense oligonucleotides in Figure 2g or the STAT3 
decoy in Figure 2j.
    Dr. Doreian has entered into a Voluntary Settlement Agreement and 
has voluntarily agreed for a period of three (3) years, beginning on 
January 15, 2013:
    (1) To have his research supervised; Respondent agreed that prior 
to the submission of an application for U.S. Public Health Service 
(PHS) support for a research project on which his participation is 
proposed and prior to his participation in any capacity on PHS-
supported research, Respondent shall ensure that a plan for supervision 
of his duties is submitted to ORI for approval; the supervision plan 
must be designed to ensure the scientific integrity of his research 
contribution; he agreed that he shall not participate in any PHS-
supported research until such a supervision plan is submitted to and 
approved by ORI; Respondent agreed to maintain responsibility for 
compliance with the agreed upon supervision plan;
    (2) That any institution employing him shall submit, in conjunction 
with each application for PHS funds, or report, manuscript, or abstract 
involving PHS-supported research in which Respondent is involved, a 
certification to ORI that the data provided by Respondent are based on 
actual experiments or are otherwise legitimately derived and that the 
data, procedures, and methodology are accurately reported in the 
application, report, manuscript, or abstract;
    (3) To exclude himself voluntarily from serving in any advisory 
capacity to PHS including, but not limited to, service on any PHS 
advisory committee, board, and/or peer review committee, or as a 
consultant; and
    (4) To request that the following paper be retracted: Mol Biol 
Cell. 20(13):3142-54, 2009 Jul.

FOR FURTHER INFORMATION CONTACT: Director, Office of Research 
Integrity,

[[Page 8149]]

1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200.

David E. Wright,
Director, Office of Research Integrity.
[FR Doc. 2013-02487 Filed 2-4-13; 8:45 am]
BILLING CODE 4150-31-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.